These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28123127)

  • 1. [Efficacy of zoledronic acid for osteoporosis:evidence from studies abroad.].
    Inoue D
    Clin Calcium; 2017; 27(2):247-255. PubMed ID: 28123127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of zoledronic acid on osteoporosis patients in Japan.].
    Tanaka S
    Clin Calcium; 2017; 27(2):257-261. PubMed ID: 28123128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid: a review of its use in the treatment of osteoporosis.
    Deeks ED; Perry CM
    Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of zoledronic acid in the prevention and treatment of osteoporosis.
    Räkel A; Boucher A; Ste-Marie LG
    Clin Interv Aging; 2011; 6():89-99. PubMed ID: 21594000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic Acid (Reclast
    Dhillon S
    Drugs; 2016 Nov; 76(17):1683-1697. PubMed ID: 27864686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit.
    Prescrire Int; 2010 Apr; 19(106):63. PubMed ID: 20568485
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 9. Zoledronic acid for prevention and treatment of osteoporosis.
    Recknor C
    Expert Opin Pharmacother; 2011 Apr; 12(5):807-15. PubMed ID: 21385149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minodronate for the treatment of osteoporosis.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
    Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis.
    Otrock ZK; Mahfouz RA; Charafeddine KM; Rayes RF; Zahed LF; Taher AT
    Ann Hematol; 2008 Nov; 87(11):947-8. PubMed ID: 18443790
    [No Abstract]   [Full Text] [Related]  

  • 12. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Tang SC
    Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous zoledronic acid: what are the indications for male osteoporosis?
    Maricic M
    Curr Osteoporos Rep; 2010 Mar; 8(1):4-9. PubMed ID: 20425084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus.
    Souza SC; Borges CT; Jorgetti V; Pereira RM
    Rev Hosp Clin Fac Med Sao Paulo; 2004 Oct; 59(5):302-5. PubMed ID: 15543404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.
    Hamdy RC
    Drug Des Devel Ther; 2010 Nov; 4():321-35. PubMed ID: 21151620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
    Miki T; Minamide T
    Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.